Evidence map›Paper›PMID 32386751›Full record

ArticleAtherosclerosis2020

Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A

Jenni Virta, Sanna Hellberg, Heidi Liljenbäck, Mia Ståhle, Johanna M U Silvola, Jenni Huusko, Mirva Söderström, Juhani Knuuti, Pirjo Nuutila, Seppo Ylä-Herttuala and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Atherosclerosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging.International journal of molecular sciences · 2022
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Jenni VirtaTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Sanna HellbergTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Department of Medicine, Karolinska Institutet, Akademiska stråket 1, SE-17164, Solna, Sweden.
Heidi LiljenbäckTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Turku Center for Disease Modeling, University of Turku, Kiinamyllynkatu 10, FI-20520, Turku, Finland.
Mia StåhleTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Johanna M U SilvolaTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Jenni HuuskoA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Neulanniementie 2, FI-70210, Kuopio, Finland.
Mirva SöderströmDepartment of Pathology, Turku University Hospital, Kiinamyllynkatu 10, FI-20520, Turku, Finland.
Juhani KnuutiTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Pirjo NuutilaTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Department of Endocrinology, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Seppo Ylä-HerttualaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Neulanniementie 2, FI-70210, Kuopio, Finland; Heart Center, Kuopio University Hospital, Puijonlaaksontie 2, FI-70210, Kuopio, Finland.
Maria F GomezDepartment of Clinical Sciences, Lund University, Jan Waldenströms gata 35, SE-21428, Malmö, Sweden.
Anne RoivainenTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Turku Center for Disease Modeling, University of Turku, Kiinamyllynkatu 10, FI-20520, Turku, Finland; Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland.
Antti SarasteTurku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Turku PET Centre, Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland; Heart Center, Turku University Hospital, Hämeentie 11, FI-20520, Turku, Finland. Electronic address: antti.saraste@utu.fi.
University of Turku · FITurku PET Centre · FITurku University Hospital · FIUniversity of Eastern Finland · FILund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsDipeptidyl peptidase 4 (DPP-4) inhibitors have anti-inflammatory and atheroprotective effects. We evaluated the effects of the DPP-4 inhibitor linagliptin on atherosclerotic plaque and hepatic inflammation using histology and 2-deoxy-2-[

methodsIgf2/Ldlr

resultsMice in linagliptin and HFD groups had similar fasting glucose concentrations, but linagliptin improved glucose tolerance. Aortas of linagliptin and HFD groups showed advanced atherosclerotic plaques with no difference in the mean intima-to-media ratio or number of macrophages in the plaques. Autoradiography showed similar

conclusionsLinagliptin therapy improved glucose tolerance and reduced hepatic inflammation but had no effect on plaque burden or atherosclerotic inflammation, as determined by histology and

Indexed as

AtherosclerosisDiabetes Mellitus, Type 2Plaque, AtheroscleroticAnimalsDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsFluorodeoxyglucose F18InflammationLinagliptinMiceMice, KnockoutPositron-Emission TomographyDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsFluorodeoxyglucose F18Linagliptin(18)F-fluorodeoxyglucoseAtherosclerosisInflammationLinagliptinType 2 diabetes

Identifiers

PMID32386751
OpenAlexW3016025062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.